Fig. 2.
Kaplan–Meier estimates of a progression-free survival and b overall survival in patients with GC/GEJC in the dose-expansion cohort (n = 40)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.